Trials that use: P-values
New to this method? Read the tutorial →
15,401 results
- DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL): Complete Statistical AnalysisIndependent statistical analysis of DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- DS-5565 Phase III Study for Post-herpetic Neuralgia: Complete Statistical AnalysisIndependent statistical analysis of DS-5565 Phase III Study for Post-herpetic Neuralgia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02318719).
- DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]: Complete Statistical AnalysisIndependent statistical analysis of DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein: Complete Statistical AnalysisIndependent statistical analysis of DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]: Complete Statistical AnalysisIndependent statistical analysis of DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]: primary endpoint results, effect estimate…
- DSAEKIndependent statistical analysis of Early Experience With Descemet's Stripping Automated Endothelial Keratoplasty: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00744796).
- DSAPIndependent statistical analysis of DSAP Treatment Comparison: 2% Lovastatin/ 2% Cholesterol vs 2% Lovastatin Alone: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- DSASIndependent statistical analysis of Depo Provera Self-Administration Study: Putting a Patient-Centered Practice to the Test at Planned Parenthood: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- DSC2UIndependent statistical analysis of An Online Health Tool About Down Syndrome: Down Syndrome Clinic to You: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- DSSIndependent statistical analysis of rTMS and Retraining in Focal Hand Dystonia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01738581).
- DSTIndependent statistical analysis of CoolSculpting of the Distal Thigh Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02335749).
- DU-176b Phase 2 Dose Finding Study in Subjects With Non-valvular Atrial Fibrillation: Complete Statistical AnalysisIndependent statistical analysis of DU-176b Phase 2 Dose Finding Study in Subjects With Non-valvular Atrial Fibrillation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Dual Antiplatelet Therapy Adherence With Reminder App Usage: Complete Statistical AnalysisIndependent statistical analysis of Dual Antiplatelet Therapy Adherence With Reminder App Usage: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05071027).
- Dual Energy CT as a Noninvasive Method to Screen for Gastroesophageal Varices: Complete Statistical AnalysisIndependent statistical analysis of Dual Energy CT as a Noninvasive Method to Screen for Gastroesophageal Varices: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- DUAL™Independent statistical analysis of A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and…
- DUAOIndependent statistical analysis of Doppler-Guided Uterine Artery Occlusion (DUAO) Device for Fibroid Related Bleeding: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00496080).
- DUARTIndependent statistical analysis of Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder: primary endpoint results, effect estimate with confidence interval, sample-size…
- DULCISIndependent statistical analysis of CO2-Laser Treatment in Patients With Diabetic Infected Foot Ulcers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02677779).
- Dulcolax vs Placebo in Functional Constipation: Complete Statistical AnalysisIndependent statistical analysis of Dulcolax vs Placebo in Functional Constipation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00526097).
- Duloxetine for Chronic Depression: a Double-blind Study: Complete Statistical AnalysisIndependent statistical analysis of Duloxetine for Chronic Depression: a Double-blind Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00360724).
- Duloxetine for Menopausal Depression: Complete Statistical AnalysisIndependent statistical analysis of Duloxetine for Menopausal Depression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01117857).
- Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome: Complete Statistical AnalysisIndependent statistical analysis of Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00114127).
- Duloxetine for the Treatment of Chronic Pelvic Pain: Complete Statistical AnalysisIndependent statistical analysis of Duloxetine for the Treatment of Chronic Pelvic Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01451606).
- Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder: Complete Statistical AnalysisIndependent statistical analysis of Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Duloxetine Treatment in Elderly With Dysthymia: Complete Statistical AnalysisIndependent statistical analysis of Duloxetine Treatment in Elderly With Dysthymia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01852383).
- DUO-EIndependent statistical analysis of Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- DUO-OIndependent statistical analysis of Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients: primary endpoint results, effect estimate with confidence…
- Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus: Complete Statistical AnalysisIndependent statistical analysis of Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52): Complete Statistical AnalysisIndependent statistical analysis of Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury: Complete Statistical AnalysisIndependent statistical analysis of DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Durability of Hypertonic Saline for Enhancing Mucociliary Clearance in Cystic Fibrosis: Complete Statistical AnalysisIndependent statistical analysis of Durability of Hypertonic Saline for Enhancing Mucociliary Clearance in Cystic Fibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Durability of Two Skin Barrier Protectants (SBP): Complete Statistical AnalysisIndependent statistical analysis of Durability of Two Skin Barrier Protectants (SBP): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05756348).
- DuraGen Plus® Adhesion Barrier for Use in Spinal Surgery: Complete Statistical AnalysisIndependent statistical analysis of DuraGen Plus® Adhesion Barrier for Use in Spinal Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00387829).
- Dural Puncture Epidural Versus Epidural Anesthesia for Cesarean Delivery: Complete Statistical AnalysisIndependent statistical analysis of Dural Puncture Epidural Versus Epidural Anesthesia for Cesarean Delivery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03915574).
- Duration of Analgesia After Popliteal Fossa Nerve Blockade: Effects of Dexamethasone and Buprenorphine: Complete Statistical AnalysisIndependent statistical analysis of Duration of Analgesia After Popliteal Fossa Nerve Blockade: Effects of Dexamethasone and Buprenorphine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine: Complete Statistical AnalysisIndependent statistical analysis of Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02037425).
- Duration of Effect of Biotene Spray in Patients With Dry Mouth: Complete Statistical AnalysisIndependent statistical analysis of Duration of Effect of Biotene Spray in Patients With Dry Mouth: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose: Complete Statistical AnalysisIndependent statistical analysis of Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Duration of Infusion Set Function: Quick-Set Teflon Catheter Versus Sure-T Steel Infusion Set Catheter: Complete Statistical AnalysisIndependent statistical analysis of Duration of Infusion Set Function: Quick-Set Teflon Catheter Versus Sure-T Steel Infusion Set Catheter: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH: Complete Statistical AnalysisIndependent statistical analysis of Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Durolane Versus Phosphate Buffered Saline (PBS) in Knee Osteoarthritis: Complete Statistical AnalysisIndependent statistical analysis of Durolane Versus Phosphate Buffered Saline (PBS) in Knee Osteoarthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01753830).
- Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC: Complete Statistical AnalysisIndependent statistical analysis of Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04786093).
- Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC: Complete Statistical AnalysisIndependent statistical analysis of Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Durvalumab and Tremelimumab for Pediatric Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Durvalumab and Tremelimumab for Pediatric Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03837899).
- Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03435107).
- Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size…
- DUS on the Prescribing Indications for CPA/EE in 5 European Countries: Complete Statistical AnalysisIndependent statistical analysis of DUS on the Prescribing Indications for CPA/EE in 5 European Countries: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH): Complete Statistical AnalysisIndependent statistical analysis of Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…